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ABSTRACT 
Chronic hepatitis C virus (HCV) infection is often asymptomatic until an occurrence of severe liver 
disease. A descriptive cross-sectional study was conducted of a hospital-based case-series in 2014 
on 741 consecutive HCV patients presented at the national referral center in Malaysia, a middle-
income Southeast Asian country. Mean age at initial presentation was 48 years (SD =11.5; median = 
49) with 541 (73%) males. Prior known exposure to HCV risk factors were intravenous drug use (n = 
271/737) and blood product transfusion (n = 237/737). HCV-genotype distributions were G3 (37.1%), 
G1 (21.4%), G2 (0.3%), G4 (0.1%) and G6 (0.1%), with 41.0% untested. Cirrhosis and non-cirrhotic 
chronic infection was present in 44 [mean (SD) age = 52 (9) years and 56% (mean (SD) age = 44 (12) 
years] patients, respectively. Of the 327 cirrhotic patients, 36% and 14% had decompensated 
cirrhosis and hepatocellular carcinoma respectively. Eighty percent patients were eligible for 
interferon treatment based on their stage of liver disease, but only 50% of the eligible patients 
received the treatment. Thus, HCV-infected patients at initial presentation to a tertiary care center in 
Malaysia reflected delayed presentation with a disproportionately high number of patients with liver 
cirrhotic. Improving access to clinical care and optimizing treatment with direct acting antiviral drug is 
essential to reduce the country’s burden of hepatitis C. 
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INTRODUCTION  
Globally, 64-103 million people are chronically infected with hepatitis C virus (HCV), while viremia 
prevalence among adults in Asia Pacific countries is 0.4-1.1% (Gower et al, 2014). In Malaysia, 2.5% 
of the population 15-64 years of age is estimated to be anti-HCV-positive in 2015 and the total adult 
population with chronic HCV infection estimated at 368,500 (McDonald et al, 2014). Worldwide 
genotype 1 accounts for 50% of hepatitis C cases followed by genotype 3 (28.6%) (Messina et al, 
2015). In Malaysia, the predominant HCV genotype is genotype 3 followed by genotype 1 ( Mohamed 
et al, 2013; Ho et al, 2015). 
Generally, 35% of individuals with acute hepatitis C achieve spontaneous viral clearance within two 
years postinfection, while the remaining progress to chronic HCV infection (Micallef et al, 2006). 
Among the chronically-infected patients, approximately 20% will develop liver cirrhosis within 20-30 
years (Westbrook and Dusheiko, 2014), which can lead to hepatic decompensation, hepatocellular 
carcinoma (HCC) and death, with hepatitis C being the leading cause of HCC and liver 
transplantations worldwide (Kim and Chang, 2013). Following the onset of cirrhosis, the annual risk of 
developing decompensated cirrhosis (DC) and HCC is 3-6% and 1-5%, respectively (Maasoumy and 
Wedemeyer, 2012; Westbrook and Dusheiko, 2014). For patients with DC, the annual mortality risk is 
15–20% (Westbrook and Dusheiko, 2014).  
Asymptomatic presentation of early hepatitis C infection often leads to many infected individuals being 
unaware of their infected state (Gupta et al, 2015; Zhou et al, 2015; Alejandro et al, 2016). Patients 
commonly are admitted into clinical care after developing clinical sequelae, which are usually 
irreversible and associated with high morbidity and mortality (Degos et al, 2000). The World Health 
Organization (WHO) recommends direct acting antiviral (DAA) regimen, such as sofosbuvir + 
velpatasvir, ledipasvir + sofosbuvir and ombitasvir + paritaprevir + ritonavir, as the current drug of 
choice for treatment of hepatitis C in place of the traditional subcutaneous interferon-based (IFN) 
therapy (WHO, 2017). 
WHO has also established the Global Health Sector Strategy 2016-2021 on viral hepatitis, which 
recommends all countries to aim for the elimination of viral hepatitis by 2030 (WHO, 2016). In order to 
develop national policies and strategies to achieve this goal, there is a need to identify hepatitis C-
infected population presenting at a local clinical care center to provide accurate information for the 
development of national policies for treatment and control of hepatitis C infection. 
Hence, this study describes the clinical characteristics and disease stages of chronic HCV-infected 
patients during initial presentations at the main national tertiary-care referral center in Malaysia. 
 
MATERIALS AND METHODS 
Study location and population 
A descriptive cross-sectional analysis was conducted of a hospital-based caseseries on consecutive 
HCV patients who presented in 2014 at the national tertiarycare referral center. Selayang Hospital, 
located in Klang valley, an area with the highest population density in the country (Department of 
Statistics Malaysia, 2010), is a public healthcare institution and the main tertiary-care referral center 
for liver diseases in Malaysia. The Hospital has the largest number of hepatologists and 
gastroenterologists among public healthcare institutions and receives referrals for liver cases from all 
over Malaysia (Hospital Selayang, 2014). 
Data on socio-demographic background and clinical characteristics of patients with chronic HCV were 
collected from Selayang Hospital medical record database from their initial presentation until the end 
of 2014. Results on HCV viral loads, genotypes and subtypes tests were collected as available in the 
database.  
Chronic HCV patients were classified into cirrhotic and non-cirrhotic types. Cirrhotic patients fulfilled 
the following criteria: (i) modified histologic activity index score of 6 based on liver biopsy results, 
and/or (ii) METAVIR score of F4 based on fibroscan result, and/or (iii) aspartate aminotransferase-to-
platelet ratio index (APRI) score ≥2 (Castéra et al, 2005). HCV patients were further classified into 
compensated and decompensated cirrhosis, with or without HCC. Severity of cirrhosis was graded 
using the Child-Pugh (CP) classification (Khullar et al, 2015). HCC was diagnosed mainly through 
dynamic imaging studies (multiphasic CT scan or MRI) or liver biopsy, with or without raised alpha-
fetoprotein levels (Galle et al, 2018).  
The study received ethics approval from the National Medical Research Registry and Ethics 
Committee of Malaysia (NMRR-15-1559-27223). 
Laboratory assays 
Identification of viral load and genotype (with or without subtype) was conducted using qualitative and 
quantitative tests for detection of HCV RNA (reverse transcription and PCR-based amplification) and 
nucleic acid sequencing, respectively (Mohamed et al, 2013; Ho et al, 2015). The latter results were 
compared with sequence information (genotype patterns) deposited at GenBank, and, in some cases, 
phylogenetic analysis was conducted to specify subtypes of the detected genotype (Mohamed et al, 
2013; Ho et al, 2015). 
Data analysis 
Data analysis was conducted using SPSS version 22.0 (IBM, Armonk, NY). 
 
RESULTS 
There were 741/5,865 (12.6%) patients with active hepatitis C infection treated by the Hepatology 
Department, Selayang Hospital, Klang valley, Malaysia in 2014. Data were collected for all 741 
patients from their first visit to the Hepatology Department until the end of 2014. Of the patients 
included in this study, 541 (73.0%) were male with mean (SD) age at initial presentation was 48 (11) 
years (median = 49). The most common age group at initial presentation was 50-59 years (n = 255, 
34.4%), followed by 40-49 years (n = 225, 0.4%). Prior known exposure to HCV risk factors obtained 
from available data for 737 patients were (in decreasing order of frequency) intravenous drug use 
(IVDU) (n = 271, 36.8%), history of blood or blood products transfusion (n = 237, 32.2%), having 
multiple sexual partners (n = 123, 16.7%), tattooing, cupping therapy, acupuncture and/or sharing of 
personal sharp items with infected individuals (n = 68, 9.2%), history of dialysis (n = 38, 5.2%), and 
recipient of organ transplantation (n = 13, 1.8%), with some patients having been exposed to multiple 
HCV risk factors. 
Of the 741 patients, 631 and 535 patients were tested for hepatitis B surface antigen (HBsAg) and 
HIV antibodies, resulting in 34 (5.4%) and 51 (9.5%) patients, respectively being positive. Four (0.5%) 
patients had triple infections (HCV, hepatitis B and HIV). 
Median (range) baseline HCV load was 3.1x106 (64 - 861.3x106) copies/ml, with high baseline viral 
load (>6 x106 copies/ ml) in 33.3% of chronic HCV patients. Of the 437 patients tested for HCV 
genotype, genotype 3 was the most common (n = 275, 63.0%) followed by genotype 1 (n = 158, 
36.1%), genotype 2 (n = 2, 0.5%), genotype 4 (n = 1, 0.2%), and genotype 6 (n = 1, 0.2%). Subtypes 
data were available for 243/275 genotype 3 and 140/158 genotype 1 patients, respectively. Numbers 
of patients with genotype 3a and 3b were 236 (97%) and 7 (3%), respectively, and with genotype 1a, 
1b and 1a/1b were 87 (62%), 49 (35%) and 4 (3%). 
At initial presentation, 414 (56%) and 327 (44%) patients were non-cirrhotic [mean (SD) age = 44 
(12); median = 45] and cirrhotic [mean (SD) age = 52 (9) years; median = 52 years]. The majority of 
cirrhotic patients (267, 82%) were <60 years of age and 209 (64%) had compensated cirrhosis [mean 
(SD) age = 53 (9); years; median = 52 years] while the remaining (36%) had decompensated cirrhosis 
[mean (SD) age = 52 (9) years; median = 52 years] (Table 1). 
The 118 decompensated cirrhosis patients were further categorized according to CP classification, 
with 92 (78%) and 26 (22%) patients in CP(B) and CP(C), respectively, while 69 (58%), 62 (45%) and 
12 (10%) patients had variceal bleeding, ascites and hepatic encephalopathy, respectively. Of the 327 
cirrhotic hepatitis C patients, 45 (14%) had HCC, with 28 (62%), 14 (31%) and 3 (7%) in CP(A), CP(B) 
and 3/45 CP(C) category, respectively. 
All patients with non-cirrhotic chronic infection and compensated cirrhosis (595/741, 80.3%) were 
considered clinically eligible for IFN therapy, assuming no other restricting factors for treatment 
initiation such as comorbidities, refusal and loss to follow-ups. Overall, 123 (20.7%) patients achieved 
sustained virologic response (SVR) following IFN therapy, among whom 99 (80%) and 24 (20%) were 
non-cirrhotic and compensated cirrhotic respectively, with 83, 39 and 1 having HCV genotype 3, 1 
and 2 infection, respectively. 
There were 262/741 (35%) patients who received treatment for HCV infection, 255 (97%) with IFN-
only treatment, 5 (2%) with both IFN and DAA and 2 (1%) with DAA drugs . Among the five patients 
who received both IFN and DAA, two received IFN, ribavirin and boceprevir for 48-weeks while three 
patients initially received IFN-based treatment and were subsequently treated with combination 
regimens of sofosbuvir, daclatasvir and ribavirin for 24 weeks, ombitasvir, paritaprevir, ritonavir, 
dasabuvir and ribavirin for 24 weeks and grazoprevir and elbasvir for 12 weeks, respectively. Among 
the two treatment-naïve patients who received DAA, both were treated with a combination regimen of 
ombitasvir, paritaprevir, ritonavir, dasabuvir and ribavirin for 12 weeks. All seven patients who 
received DAA had HCV genotype 1 infection without cirrhosis. 
Among all patients, 479 (64.6%) had viremia but did not receive treatment for HCV infection for the 
following reasons: (i) ineligible for IFN treatment due to DC and HCC (n = 146; 30%), (ii) refused 
treatment (n = 89, 19%), (iii) ineligible for IFN treatment due to such factors as comorbidity, old age or 
active IVDU (n = 85, 18%), and (iv) loss to follow-up (n = 79, 16%). The remaining (17%) patients who 
did not receive treatment because of failure to respond to previous IFN treatment, chose to be treated 
at other institutions or were awaiting a more affordable DAA. 
Table 1 - Stages of liver disease at initial presentation of hepatitis C virus -infected patients 
according to age groups at the national tertiary-care referral center, Malaysia during 2014. 
 
 Stage of liver disease 







Age group (years)    
≤39 (n = 165)  140 15 10 
40-49 (n = 225)  133 55 37 
50-59 (n = 255)  105 96 54 
≥60 (n = 96)  36 43 17 
Total  414 209 118 
 
DISCUSSION  
To the best of our knowledge, this is the first and largest study to describe clinical characteristics and 
disease stages of chronic HCV-infected patients at initial presentation at tertiary care center in 
Malaysia. Almost 50% of the hepatitis C patients at the referral center presented with liver cirrhosis, 
similar to findings from other middle-income countries (de Oliveira et al, 2014; Gupta et al, 2015). 
Based on the European Association for the Study of the Liver (EASL) definition (EASL, 2015), 
patients who present with significant fibrosis without previous antiviral treatment are considered as 
delayed presentation of chronic hepatitis C. In this study, 72% of the patients were in this category 
mainly due to unawareness of their hepatitis C status owing to the subclinical manifestations at early 
stage of infection; approximately 75-80% of HCV infected individuals are asymptomatic and only 
become aware of the infection after serological testing is conducted (Zhou et al, 2015). This delayed 
presentation is particularly of concern among Asian hepatitis C patients, who have no clear risk 
factors for HCV acquisition compared to other ethnicities, such as Caucasians and Hispanics, but in 
fact are at risk due to such common practices in Asian countries as acupuncture, sharing shaving kit 
and use of roadside barber (Nguyen and Nguyen, 2013). These common practices make a risk-based 
screening strategy challenging as it becomes difficult to identify a high-risk group among the general 
population, besides the obvious high-risk population of IVDU and those with a history of blood 
transfusion (Nguyen and Nguyen, 2013; Suthar and Harris, 2015). 
The time lag from HCV diagnosis to tertiary care referral is also an important factor in the delayed 
presentation for clinical management of HCV patients (Yau et al, 2015). In Malaysia, there is a paucity 
of data on referral rate or time between diagnosis of hepatitis C at a primary care center and 
presentation at a tertiary care institution, with an estimated referral rate (from primary care to 
hepatology or gastroenterology specialist care) of 13% in 2016 in 10 of 12 states in Malaysia, the 
main reason being patient’s refusal of IFN therapy, which was previously the main option for HCV 
treatment before the introduction of DAA drugs within the national public health care system (Ali N,  
personal communication). Malaysia is an example of a middle-income Asian country that recently (in 
2018) has DAA drugs available in the national public healthcare system as the main treatment option 
for HCV disease, and thus, the treatment rate presented in this study mainly reflected previous use of 
IFN therapy. 
Delayed presentation at advanced stage of liver disease has significant impact on (i) HCV-infected 
individual in term of lower success rate of treatment (The American Association for the Study of Liver 
Diseases and Infectious Diseases Society of America, 2017), (ii) healthcare system with regards to 
higher healthcare utilizations and healthcare costs for disease management (Razavi et al, 2013; 
Myers et al, 2014; Azzeri et al, 2017), and (iii) society at large due to risk of transmission of an on-
going disease in the general population (Hickman et al, 2015). 
Globally, DAA drugs are now widely used for the treatment of HCV infection. The predominant HCV 
genotypes in Malaysia are genotype 3 followed by genotype 1, accounting for 99% of all HCV cases 
(Mohamed et al, 2013; Ho et al, 2015). This implies that any DAA regimen with proven efficacy for 
these two genotypes could be adopted within a simple management protocol. Standard use of such 
DAA regimens for all non-cirrhotic and cirrhotic patients would remove the need for genotyping and 
thus will further expedite initiation of treatment for all HCV infected patients. Hypothetically, if DAA is 
available as standard HCV treatment for this study population (as compared to the previously use of 
IFN), the proportion of patients who would be eligible for HCV treatment will rise to 94% compared to 
80% due to the wider eligibility for DAA treatment for patients, including those with decompensated 
cirrhosis, assuming no other restricting factors for treatment initiation, such as comorbidity, refusal 
and loss of follow-up. 
However, HCV-infected patients with advanced liver disease have been known to achieve lower SVR 
rates with DAA compared to patients without cirrhosis or with compensated cirrhosis (Curry et al, 
2015; Foster et al, 2015). There also is evidence indicating improvements in the symptoms of liver 
disease after treatment with DAA among patients with decompensated cirrhosis, while CP(C) is not 
sufficient in preventing the need for liver transplantation or mortality (The American Association for the 
Study of Liver Diseases and Infectious Diseases Society of America, 2017). This highlights the 
importance of early presentation for initiation of treatment at the early stages of liver disease among 
HCV patients.  
This study finds, at initial presentation at a tertiary care center, cirrhotic patients were relatively young 
and the majority of patients with cirrhosis (with or without HCC) were less than 60 years of age.  
Development of liver cirrhosis among relatively young HCV-infected patients may reflect use of illicit 
drugs before 20 years of age (Novick et al, 1985), which represents the biggest risk factor for HCV 
transmission in Malaysia (Vicknasingam et al, 2009) with liver cirrhosis developing 25 to 30 years 
following initial exposure to infection (Thein et al, 2008). 
Several other factors may contribute to the observation of liver cirrhosis at a young age in this study 
cohort. The majority of the patients were male and infected with HCV genotype 3, factors associated 
with rapid fibrosis progression in hepatitis C disease (Maasoumy and Wedemeyer, 2012; Toshikuni et 
al, 2014; Lingala and Ghany, 2015). Development of cirrhosis at a relatively young age has also been 
observed in other studies (Sajja et al, 2014; Silva et al, 2015; McDonald et al, 2017). The 
development of liver cirrhosis among relatively young patients who are in the working-age group may 
lead to financial problems to the patients and their families due to loss of income, lower productivity 
and significant time and costs for treatment (Federico et al, 2012; Scalone et al, 2015). Patients in this 
group are potential breadwinners of the family and hepatitis C disease can cause them to be less 
economically productive owing to reduced ability to work and potential job loss from illness (Scalone 
et al, 2015). Cirrhotic patients spend 7% of their annual income for clinical treatment and have 
significant time loss from work due hospitalization and visits to clinics (Federico et al, 2012). 
However, the findings of this study must be interpreted with caution. The use of a retrospective 
hospital database may have led to variations in the availability of patients’ information from medical 
records, which in turn could have resulted in missing such data as baseline viral load, virus 
genotypes, risk factors and SVR achievement rates. In order to minimize this inherent weakness, 
relevant data (as much as possible) were requested from other available records within the hospitals. 
As this study was conducted at a national tertiary care referral center, the distribution of disease 
stages could potentially be disproportionate towards the more severe stages (referral bias). In 
addition, while the number of patients in the present study is small, the sparse available evidence 
suggests only a small proportion of symptomatic HCV patients were in tertiary care, possibly due to 
the low referral rate and the previous lack of treatment alternatives to IFN (Mohamed R, personal 
communication). Being the main national referral center for liver disease with the highest numbers of 
hepatologists and gastroenterologists among Malaysia public hospitals, the patients’ population in this 
hospital is likely a good reflection of the affected population treated within tertiary care in Malaysia 
and the findings in this represent the best available epidemiological data for the country. 
In conclusion, this study reveals a relatively high percent liver cirrhosis among HCV-infected patients 
at initial presentation to a tertiary care center in Malaysia, reflecting delayed referral. The findings also 
highlights the high number of relatively young patients with cirrhosis at presentation. Data from this 
study emphasize the importance of timely referral, links to tertiary clinical care centers and the 
necessity of increasing awareness of HCV infection in the general population. Access to affordable 
DAA drugs for treatment of hepatitis C within the public healthcare system of Malaysia is essentialif 
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